Clinical trial · Interventional
Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
An Open, Single Center Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After TKI Therapy
NCT01963195CI-TRIAL-00027404unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy and safety of dose escalation of Icotinib in advanced non small cell lung cancer (NSCLC) patients after the therapy of Icotinib, Iressa and Tarceva.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Icotinib | Drug | Icotinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Icotinib
- description
- Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicity occurred. The overall study period takes about 24 months
- interventionNames
- Drug: Icotinib
Primary outcomes (1)
- measure
- safety and efficacy
- timeFrame
- 2 years
- description
- 1. The efficacy of dose escalation of Icotinib in advanced NSCLC patients after failure of TKI (Icotinib 125mg po tid. Iressa 250mg po qd. Tarceva 150mg po qd) therapy will be evaluated according to the revised RECIST 1.1 (Response Evaluation Criteria In Solid Tumors). 2. The safety of high dosage of Icotinib will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. NSCLC patients were confirmed by histology or cytology 2. The time interval must be over 4 weeks from previous chemotherapy to registration to participate in this experiment if he or she received chemotherapy,and also have any toxicity to recover. 3. at least one measureable lesion accord to RECIST 1.1 criteria and the lesion accepted no radiotherapy. * 1 at least one measureable lesion .if only one measureable lesion, the biological nature must be confirmed by cytology or histology. * 2 a single diameter of lesion could be measured by at least one of the following methods: Chest or abdominal computed tomography(CT)or magnetic resonance imaging(MRI),conventional methods of diameter at least 20mm diameter spiral CT OR at least 10mm. 4. ECOG 0-2 score 5. at least 12 weeks of expected survival time 6. Women of childbearing age must have a pregnancy test 7 days before treatment and the result were negative ,men of childbearing age: surgical sterilization or treatment during and after the end of three months to take contraceptive measures 7. understand and sign a written informed consent voluntarily. Exclusion Criteria: If the subject meet any of the following exclusion criteria ,he is no eligible to participate in this study, 1. Before enrollment in this trial have used Erbitux, Herceptin and carried out anti-cancer therapy. 2. use of phenytoin, carbamazepine, rifampicin, phenobarbital or St. John's Wort when take this trial 3. severe allergies to Icotinib
References
Publications (0)
Data not yet available
No reference posted for this study.